Noon and Al-Ittihad score partnership deal

The partnership was sealed at a signing ceremony attended by Dr. Yasser Nassif, Al-Ittihad CEO; Abdullah Kaboha, member of Al-Ittihad board of directors; Mohamed Alabbar, Noon founder; and Khalid Balghunaim, Noon director of KSA operations.
Updated 12 December 2018

Noon and Al-Ittihad score partnership deal

Two of the region’s favorite pastimes, football and shopping, meet in a major partnership deal between Al-Ittihad Club Saudi Arabia and Noon that will see the digital marketplace become the main sponsor of the champion football club.

Noon’s partnership with Al-Ittihad, one of the Kingdom’s oldest football clubs, is expected to further strengthen the brand’s foundations in the region it was born.

The partnership was sealed at a signing ceremony attended by Dr. Yasser Nassif, Al-Ittihad CEO; Abdullah Kaboha, member of Al-Ittihad board of directors; Mohamed Alabbar, Noon founder; and Khalid Balghunaim, Noon director of KSA operations.

Alabbar said: “Sponsoring Al-Ittihad, a team with a long history of great achievements, is an honor for us. We’re also excited to connect with Al-Ittihad’s dedicated fan base.”

Loay Nazer, Al-Ittihad president, said: “I would like to thank Noon for their trust and dedication to Al-Ittihad, one of the most beloved football clubs with a history of many formidable achievements.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.